Pfizer, BioNTech Now Seeking Full Approval For Third COVID-19 Vaccine Dose

Pfizer Inc PFE and BioNTech SE BNTX have initiated supplemental marketing application to the FDA seeking approval for its COVID-19 booster (third) shot.
Earlier this week, Pfizer-BioNTech's COVID-19 Vaccine Became First To Receive Full FDA Approval.
The application covers individuals 16 years of age and older. The companies plan to complete the submission by the end of this week.
The application includes data from a Phase 3 trial of 306 participants 18-55 years of age.
The FDA has already approved Booster Dose Of mRNA COVID-19 Vaccines For Small, Vulnerable Group.
Today, European Medical Agency approved additional manufacturing sites for coronavirus vaccines from Pfizer/BioNTech and Moderna Inc MRNA.
Related content: Benzinga's Full FDA Calendar
Price Action: PFE shares are down 1.88% at $47.47, BNTX stock is up 1.01% at $371.91 during the market session on the last check Wednesday.
Photo by x3 from Pixabay